What is the Historical Analysis of the Non-Alcoholic Steatohepatitis (NASH) Market Size?
The non-alcoholic steatohepatitis (nash) market has seen considerable growth due to a variety of factors.
• In recent years, there has been an enormous growth in the non-alcoholic steatohepatitis (NASH) market size. This market is projected to expand from $4.5 billion in 2024 to $6.13 billion in 2025, with a compound annual growth rate (CAGR) of 36.1%.
The growth observed during the historic period is linked to several factors including an increase in NASH prevalence, an obesity crisis, enhanced awareness and diagnoses, alterations in lifestyle and diet patterns, and advancements in healthcare infrastructure.
What are the Forecasted Growth and Key Factors of the Non-Alcoholic Steatohepatitis (NASH) Market?
The non-alcoholic steatohepatitis (nash) market is expected to maintain its strong growth trajectory in upcoming years.
• Forecasts suggest that the size of the non-alcoholic steatohepatitis (NASH) market will experience significant expansion in the upcoming years, potentially reaching a value of $19.07 billion in 2029, equating to a compound annual growth rate (CAGR) of 32.8%.
Factors contributing to growth during the projection period include enhancements in NASH drug creation, amplified initiatives for NASH screening, an escalation in healthcare expenditure, joint research efforts, and government support and rules. Notable trends expected within this period include increased attention towards lifestyle interventions and patient awareness, strengthened collaborative efforts in clinical studies, regulatory progression and pathway assignments, and the incorporation of artificial intelligence into diagnosis and monitoring processes.
What Are the Critical Driver Fuelling the Non-Alcoholic Steatohepatitis (NASH) Market's Growth?
The surge in obesity incidents is bolstering the non-alcoholic steatohepatitis (NASH) market's growth. Obesity, a condition characterized by abnormal or excessive fat accumulation that presents a health risk, typically consists of a body weight that exceeds what is considered healthy or average for a person's height. The occurrence of non-alcoholic fatty liver disease has increased due to the escalating obesity crisis, potentially making NASH the leading cause of advanced liver disease in the coming years and thereby spurring the need for NASH treatments and associated medications. For instance, in March 2024, the World Health Organization (WHO), a UK-based international public health organization, indicated that in 2022, around 2.5 billion adults over the age of 18 were categorized as overweight, with obesity affecting 890 million of them. Hence, the growing number of obesity cases will fuel the non-alcoholic steatohepatitis (NASH) market's expansion.
How Is the Non-Alcoholic Steatohepatitis (NASH) Market segmented?
The non-alcoholic steatohepatitis (NASH) market covered in this report is segmented –
1) By Type: Solid, Liquid
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider
5) By Application: Oral, Parenteral
Subsegments:
1) By Solid: Tablets, Capsules, Other Solid Dosage Forms
2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms
Pre-Book The Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing the Non-Alcoholic Steatohepatitis (NASH) Market?
Prominent businesses in the non-alcoholic steatohepatitis (NASH) market are utilizing thyroid hormone receptor-beta (THR-beta) agonists to improve liver metabolism, lessen the buildup of fat in the liver, and boost liver functionality. These THR-beta agonists are substances that selectively prompt the thyroid hormone receptor-beta subtype, an essential receptor in controlling metabolism, growth, and development. For example, in March 2024, the Food and Drug Administration, a US regulatory agency, sanctioned the use of Rezdiffra (resmetirom), a thyroid hormone receptor-beta agonist, as an inaugural treatment for adults with noncirrhotic NASH with moderate to severe liver fibrosis. Rezdiffra, by selectively targeting the THR-beta receptor, helps manage lipid metabolism, thereby decreasing intrahepatic triglycerides and overall liver fat.
Who Are the Key Players in the Non-Alcoholic Steatohepatitis (NASH) Market?
Major companies operating in the non-alcoholic steatohepatitis (NASH) market include:
• NGM Biopharmaceuticals Inc.
• Novartis AG
• AstraZeneca plc.
• GlaxoSmithKline plc.
• F. Hoffmann-La Roche AG
• The Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Novo Nordisk A/S
• Genfit SA
• Cadila Pharmaceuticals Ltd.
• Intercept Pharmaceuticals Inc.
• Enanta Pharmaceuticals Inc.
• Blade Therapeutics Inc.
• Galmed Pharmaceuticals Inc.
• Immuron Limited
• Terns Pharmaceuticals Inc.
• Tobira Therapeutics Inc.
• Arena Pharmaceuticals Inc.
• Galectin Therapeutics Inc.
• Viking Therapeutics
• Madrigal Pharmaceuticals Inc.
• Cirius Therapeutics
• Akero Therapeutics Inc.
• Echosens.
What Is The Most Dominant Region In The Non-Alcoholic Steatohepatitis (NASH) Market?
North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
